Surprisingly, other immune cell populations and effector cell functions that are typically altered through tumor PDL1 depletion (e.g., IFNγ+ CD8+ T cells, Granzyme expression) were unaffected by cefepime treatment (Supplementary Figure S3), which suggests differential immune consequences of PDDs. The gene discussed is CD8A; the disease is neoplasm.